Introduction
The interaction of proteins and drugs affects the pharmacological behavior, toxicity, and metabolism of drugs. In contrast, the binding of drugs to a certain protein may lead to an alteration in the secondary structure of the protein. Only a free drug can diffuse from the blood to a target (1) . Thus, binding of a drug and protein affects the metabolism and action of that drug. Examining the interaction of a protein and a drug helps to understand the pharmacokinetics and pharmacodynamics of that drug.
Riociguat (Figure 1 ), a stimulator of redox-sensitive soluble guanylate cyclase, is the only drug approved for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (2) (3) (4) . After oral administration, riociguat is transported through the bloodstream to the tissues and organ, and the therapeutic efficacy of riociguat is directly related to its free concentration in blood plasma (5) . In addition, serious adverse events have been noted after riociguat monotherapy and are associated with the plasma concentration (6) . Thus, the ability of riociguat to bind to plasma proteins is critical for its metabolism and efficacy.
To the extent known, the mechanism by which riociguat binds to plasma proteins has not been studied thus far. Human serum albumin (HSA) is the prominent transport protein in human plasma, and it plays an important role in the storage and transportation of numerous compounds including drugs and other substances (7) . HSA consists of three homologous domains -I, II and III -each of which is divided into two subdomains (A and B). The main binding sites include site I (subdomain IIA), which is marked by warfarin, and site II (subdomain IIIA), which is marked by ibuprofen (8, 9) . The ability of a drug to bind to HSA is an important factor for its efficacy and metabolism. Examining the binding of drugs to HSA may explain the structural features that affect the pharmacokinetic and pharmacodynamics of those drugs. Therefore, the binding interaction of riociguat and HSA needs to be promptly examined.
The current study used fluorescence, Fouriertransform infrared (FT-IR) spectroscopy, circular dichroism (CD), and molecular docking to examine the intermolecular interaction between riociguat and HSA. The form of binding, the association constant, the change in the protein secondary structure, and the site where riociguat bound to were determined. Findings should have great significance in terms of studying the process of storage and transportation of riociguat in the body and its mechanism of action and pharmacokinetics.
Materials and Methods

Chemicals and Reagents
A reference standard of riociguat (≥ 98%) was purchased from Ark Pharm, Inc. (Chi., USA). HSA was purchased from Solarbio Science & Technology Co. Ltd. (Beijing, China). Tris-(hydroxymethyl aminomethane) (Tris) (≥ 99%) and sodium chloride (≥ 99.5%) were purchased from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). Ibuprofen (≥ 99%) was purchased from Inno Chem Science & Technology Co., Ltd. (Beijing, China). Warfarin (≥ 98%) was purchased from Adamas Reagent Co., Ltd. (Shanghai, China). Methanol (HPLC-grade) was purchased from Fisher Chemical Co., Ltd. (Shanghai, China).
Sample preparation
A stock solution of riociguat (10 mM) was prepared in methanol solution. HSA was dissolved in 0.05 M Tris-HCl buffer solution containing 0.1 M NaCl (pH = 7.4). Both warfarin and ibuprofen were dissolved in a mixture of methanol and Tris-HCl buffer solution to obtain a concentration of 1.2 × 10 -4 M. All solutions were prepared at room temperature and stored at 4℃.
The final concentration of methanol in the test solutions was less than 2.4%, so the properties of HSA were not affected by methanol (10).
Fluorescence measurements
A Varian Cary Eclipse Spectrophotometer (Varian, Australia) with a 2-mm quartz cell was used to measure fluorescence spectra. The excitation wavelength for HSA-riociguat was 280 nm, and the emission spectrum was recorded from 290 to 450 nm. The widths of the excitation and emission slits were both set at 10 nm. The quenching effect of riociguat on HSA was investigated at three different temperatures of 288 K, 298 K, and 308 K. A mixture of riociguat and HSA were prepared with a constant HSA concentration of 2 μM (11, 12) . The concentration of riociguat varied from 0-12 μM. Synchronous fluorescence spectra were recorded at different scanning intervals of Δλ (Δλ = 60 nm and 15 nm) at room temperature.
CD measurements
The CD spectra of HSA with or without riociguat were recorded using an Applied Photophysics circular dichroism spectropolarimeter (Applied Photophysics Ltd. Leatherhead, UK). The wavelength range scanned was 200-400 nm with a 1-mm quartz cell. The data were obtained with an interval of 1 nm and a scan rate of 164 nm/min.
FT-IR Measurements
FT-IR spectra were recorded using a Nicolet 6700 FT-IR spectrophotometer (Thermo Nicolet, Madison, America). The concentration of HSA was 1 mM and that of riociguat was 0.4 mM. The sample solutions were placed in a smart ITX diamond sampler. For all spectra, 100 scans recorded at a resolution of 4 cm -1 . Data were analyzed using Nicolet OMNIC software. The second derivative resolution enhancement was performed to determine the position of each peak when peaks overlapped, and peaks were fitted using a Gaussian peak function.
Site marker competitive binding
Site marker competitive binding experiments were conducted using warfarin (as site I marker) and ibuprofen (as site II marker). In the fluorescence experiments, the concentrations of HSA and site markers were both 2 μM, while the concentration of riociguat gradually increased from 0 to 12 μM.
Molecular docking
AutoDock vina 1.1.2 was used to determine how As shown in Figure 2A , the fluorescence intensity of HSA decreased gradually with the increase in riociguat at around 334 nm. The fluorescence quenching data were analyzed using the Stern-Volmer equation (Eq. (1)) (20, 21) .
In the equation, F 0 and F are the steady state fluorescence intensities in the absence and presence of a quencher, respectively. K SV is the Stern-Volmer quenching constant and [Q] is the concentration of the quencher (riociguat). K q is the bimolecular quenching rate constant and t 0 is the fluorescence lifetime of HSA. The Stern-Volmer plots of the fluorescence of HSA quenched with riociguat at different temperatures are shown in Figure 2B , and the values of K SV and K q at different temperature are shown in Table 1 . Results indicated that the mechanism by which riociguat quenched the fluorescence of HSA was static quenching due to the formation of a riociguat-HSA complex.
Binding constant and thermodynamic parameters
When examining the binding interaction of riociguat and HSA, the binding constant (K b ) and the number of binding sites (n) can be determined using the equation as follow (Eq. (2)) (22) .
where K b is the binding constant and n is the number of binding sites for a riociguat-HSA complex. The Lineweaver-Burk plots at different temperatures are shown in Figure 2C , and the parameters are shown in Table 1 . The calculated values of n were approximately equal to 1, indicating the existence of a single binding site for riociguat on HSA. The estimated value of K b was 1.55 × 10 4 M −1 at 298 K, suggesting that strong interaction of riociguat and HSA.
Thermodynamic variables were calculated using the van't Hoff equation:
riociguat bound to HSA (13) . The three-dimensional (3D) structure of HSA (PDB ID: 2BXB) was downloaded from the Protein Data Bank (PDB) (14) . The 2D structure of riociguat was drawn using ChemBioDraw Ultra 12.0 and converted to a 3D structure using the software ChemBio3D Ultra 12.0. The AutoDockTools 1.5.6 package was used to generate docking input files (15, 16 
Results
Fluorescence measurements
Fluorescence quenching is considered to be an effective and sensitive method with which to investigate the interaction of small molecules and proteins. The intrinsic fluorescence of HSA is mainly due to tryptophan (Trp), tyrosine (Tyr), and phenylalanine (Phe) residues. Shifts in λ max and fluorescence intensity, which are mainly attributed to changes in the position of the Trp residues, were used to study HSA-riociguat interaction (18, 19) . where K is the binding constant at temperature T, and the R is the gas constant. The van't Hoff plot for the interaction of riociguat and HSA is shown in Figure 2D , and the thermodynamic parameters are shown in Table  1 . If the ΔH and ΔS are > 0, then the binding force is hydrophobic interaction. A negative ΔH and ΔS usually indicates the presence of hydrogen bonding and/or van der Waals forces. If ΔH is < 0 and ΔS is > 0, an electrostatic force is identified (23) (24) (25) (26) . In the current study, ΔG was negative, so the binding of riociguat to HSA was a spontaneous process. The positive values of both ΔH and ΔS revealed that the main force was hydrophobic interaction when riociguat bound to HSA.
Melanoma specimens
Characteristic information on Tyr and Trp residues can be obtained from synchronous fluorescence spectroscopy when the scanning interval Δλ (Δλ = λ em -λ ex ) is set at 15 and 60 nm (27, 28) . Figure 3A and 3B show the synchronous fluorescence spectra of HSA with various concentrations of riociguat, and the spectra were recorded with Δλ = 15 and 60 nm, respectively. A slight red shift in the maximum emission was observed at Δλ = 60 nm, suggesting that the hydrophobic environment surrounding Trp decreased slightly with the addition of riociguat. The intensities of both Trp and Tyr residues decreased, indicating that the quenching of HSA involved Trp and Tyr. Conformation of the protein changed upon interaction with riociguat.
CD spectroscopy
The CD spectra of HSA with and without riociguat are shown in Figure 3C . CD was calculated using the mean residue ellipticity (MRE) in deg cm 2 dmol −1 according to the following equation:
where MER 208 is the mean residue ellipticity at 208 nm, C p is the molar concentration of HSA, n is the number of amino acid residues (585), l is the path length (0.1 cm). 4,000 is the MRE of the β-form and random coil conformation cross at 208 nm, and 33,000 is the MRE value of a pure α-helix at 208 nm. Using the above equation, the α-helicity in free HSA was 55.95%. After the addition of riociguat at 6 and 12 µM, the α-helical content increased from 55.95% to 58.01% and then to 59.49%. The structure of albumin was altered by riociguat.
FT-IR Spectra
To further investigate the changes in the structure of HSA, second derivative resolution enhancement and cure fitting were performed, as shown in Figure 4 . Figure 4A and 4B show the FT-IR fitting curves of HSA in the absence and presence of riociguat in TrisHCl buffer in the region of 1,700 -1 ,600 cm -1 . Changes in peak positions and peak shapes indicated that riociguat induced a slight change in the secondary structure of HSA with binding toward the C=O groups. According to the quantitative analysis of the secondary structure, the α-helix content increased 8.16% as a result of the addition of riociguat. These results coincided with the CD spectra.
Site marker competitive binding
Two main specific drug-binding sites of HSA have previously been reported, including site I (subdomain IIA) and site II (subdomain IIIA). In the current study, warfarin (as site I marker) and ibuprofen (as site II marker) were used as site markers to investigate the binding site of riociguat on HSA. K SV and K b in a system of HSA and site markers were recorded as the concentration of riociguat increased, and the results are shown in Table 2 . K b and K SV markedly decreased in the presence of warfarin while the values were almost the same in the presence of ibuprofen. Results indicated that riociguat and warfarin competitively bound to HSA. The binding site of riociguat on HSA was primarily located on site I of HSA. Figure 5 shows the binding site of the HSA and the docking results. Riociguat docked in site I (subdomain IIA), and the overall view is shown in Figure 5A . Riociguat assumed a compact conformation to enter of the pocket of HSA, and a detailed view is shown in Figure 5B . The 2-fluorophenyl of riociguat stretched into the hydrophobic pocket that consisted of Leu-260, Ala-261, Ile-264, Ile-290, and Ala-291, forming a stable hydrophobic bond. The pyrimidine scaffold of riociguat participated in π-π stacking interaction with the residue Tyr-150. In addition, cation-π interactions between riociguat and the residues Lys-199, Arg-222, and Arg-257 were observed. Importantly, five hydrogen bond interactions were identified between riociguat and the residues Tyr-150, Glu-153, and Arg-257 of HSA. The above molecular simulations provided a good structural basis on which to explain the quenching of HSA fluorescence in the presence of riociguat.
Molecular docking
Discussion
HSA is widely used in biophysical, biochemical, and physicochemical studies since it has been extensively studied with different small molecules and its primary structure is well known. The weak binding of ligands to HSA results in a short lifetime or poor distribution of compounds since strong binding leads to a decrease in the concentration of free ligands in plasma. Thus, the interaction between a drug and HSA will affect its metabolism, distribution, toxicity, and elimination from the circulation. Riociguat is rapidly absorbed and its concentration subsequently decreases. It has a terminal half-life in the range of 5 to 10 hours, and its plasma binding rate is approximately 95% (29) . The current study of the interaction between riociguat and HSA will help to understand the process of riociguat metabolism.
Fluorescence quenching is a decrease in the quantum yield of fluorescence induced by a variety of molecular interactions with a quencher molecule. Protein conformational transitions, biomolecule binding, denaturation, and other factors are responsible for the decrease in the intrinsic fluorescence of protein. Thus, fluorescence quenching is widely used to explore the binding of biomolecules and active small molecules. Fluorescence quenching can be caused by collisions or by ground-state complex formation between a fluorophore and a quencher. The former is referred to as dynamic quenching while the latter is referred to as static quenching (21) . If the value of K SV decreases with increasing temperature and the k q value is much greater than the maximum diffusion collision quenching rate constant (2.0 × 10 10 L/mol s) of HSA with a variety of quenchers (30, 31) , then the mechanism by which a compound quenches the fluorescence of albumin is static quenching due to the formation of a compound-HSA complex. In the current study, riociguat bound to HSA via static quenching.
This study used fluorescence, FT-IR spectroscopy, CD spectroscopy, and molecular docking to conduct the first detailed investigation of the interaction between riociguat and HSA. Results indicated that riociguat effectively quenched the intrinsic fluorescence of HSA via static quenching. The binding process was spontaneous, and the main force was hydrophobic interaction. Conformational results from CD and FT-IR spectra revealed that the binding of riociguat to HSA induced some micro-environmental and conformational changes. The current results will help to better understand aspects of pharmacokinetics such as drug metabolism, excretion, and distribution. 
